Announcement on Resignation of Independent Director
Filed with SSE · · 2 pages · Chinese
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- Announcement on Voluntary Disclosure of Inclusion GR1803 Injection in the List of Priority Review Drugs
- Announcement on Voluntary Disclosure on the Acceptance of Conditional Listing Application for GR1803 Injection
- Announcement on Changing Signatory Certified Public Accountant
- Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog
- Announcement on Resolutions of the 5th Meeting of the 2nd Board of Directors
Later from Chongqing Genrix Biopharmaceutical
- Earnings Preannouncement for 2025
- Announcement on Resolutions of the 6th Meeting of the 2nd Board of Directors
- Announcement on Voluntary Disclosure on Acceptance of Marketing Application for Tallecimab Injection for Adult Seasonal Allergic Rhinitis
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Opening of a New Special Account for Raised Funds and Signing of a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical